Sareum (LON:SAR) Trading Down 16.2% – Here’s Why

Shares of Sareum Holdings plc (LON:SAR) traded down 16.2% during mid-day trading on Thursday . The stock traded as low as GBX 13.50 ($0.18) and last traded at GBX 13.82 ($0.18). 2,736,873 shares traded hands during trading, an increase of 1,131% from the average session volume of 222,414 shares. The stock had previously closed at GBX 16.50 ($0.21).

Sareum Stock Performance

The company has a market cap of £17.27 million, a price-to-earnings ratio of -3.27 and a beta of -1.08. The firm’s 50-day moving average price is GBX 19.93 and its 200 day moving average price is GBX 24.41.

Sareum Company Profile

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.